Drugs & TargetsFree Venclyxto receives EC approval in combination with a hypomethylating agent for patients with newly diagnosed aml who are ineligible for intensive chemotherapy May 28, 2021Vol.47 No.21
Drugs & TargetsFree Quest Diagnostics, Paige collaborate to advance AI-generated pathology insights to improve cancer diagnosis and care May 28, 2021Vol.47 No.21
Drugs & Targets Opdivo receives FDA approval for resected esophageal or GEJ cancer May 21, 2021Vol.47 No.20
Drugs & Targets FDA launches crowdsourcing challenge to solicit input on research questions to be addressed through agency’s oncologic clinical trial data May 21, 2021Vol.47 No.20
Drugs & TargetsFree Keytruda receives FDA Accelerated Approval for HER2-positive gastric cancer May 07, 2021Vol.47 No.18
Drugs & TargetsFree Tibsovo sNDA receives FDA acceptance and Priority Review for IDH1-mutated cholangiocarcinoma May 07, 2021Vol.47 No.18
Drugs & TargetsFree Opdivo sBLA receives FDA acceptance and Priority Review for adjuvant treatment for patients with muscle-invasive urothelial carcinoma May 07, 2021Vol.47 No.18
Drugs & TargetsFree Xtandi approved by European Commission for men with metastatic hormone-sensitive prostate cancer May 07, 2021Vol.47 No.18
Drugs & TargetsFree Janssen submits Marketing Authorization Application to EMA seeking approval of cilta-cel for relapsed and/or refractory multiple myeloma May 07, 2021Vol.47 No.18
Drugs & Targets Zynlonta receives FDA accelerated approval for large B-cell lymphoma April 30, 2021Vol.47 No.17
